Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Long LLY ETF

23.82
-0.0100-0.04%
Post-market: 23.78-0.0400-0.17%19:59 EDT
Volume:147.06K
Turnover:3.55M
Market Cap:46.33M
PE:- -
High:24.85
Open:24.50
Low:23.60
Close:23.83
52wk High:31.19
52wk Low:12.18
Shares:1.95M
Float Shares:1.95M
Volume Ratio:0.55
T/O Rate:7.56%
Dividend:0.70
Dividend Rate:2.95%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Moderately bullish activity in Eli Lilly with shares down 1.26%

TIPRANKS
·
Sep 01

Top Midday Stories: Stocks Fall, Oil Rises Amid Renewed Fighting in Middle East; Utility Shares Fall After California Wildfire Legislation

MT Newswires Live
·
Aug 31

Dow Jones Top Company Headlines at 11 am ET: GameStop Sees Higher Profit as eBay Investment Offsets Lower Sales | SLB ...

Dow Jones
·
Aug 31

Lilly is Bigger than Ever. Why Its Latest $2.9 Billion Immunology Deal Makes Sense.

Dow Jones
·
Aug 31

Eli Lilly's Psoriasis Drug Trial Shows Sustained Positive Results

Dow Jones
·
Aug 31

Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What it Means for the Stock.

Dow Jones
·
Aug 31

Eli Lilly announces 52-week results from TOGETHER-PsO, TOGETHER-PsA

TIPRANKS
·
Aug 31

Eli Lilly - Taltz and Zepbound Lead to Deeper Improvements in Systemic Inflammation in Both Trials

THOMSON REUTERS
·
Aug 31

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Showed Improved and Durable Efficacy at One Year in Adults with Psoriatic Disease and Obesity

THOMSON REUTERS
·
Aug 31

Eli Lilly - Taltz and Zepbound Maintain or Improve Disease Activity at Week 52 Versus Taltz Alone

THOMSON REUTERS
·
Aug 31

Eli Lilly: Adverse Events in Participants Treated with Taltz and Zepbound Together were Generally Mild to Moderate

THOMSON REUTERS
·
Aug 31

Lilly to Acquire Merida Biosciences in Deal Worth up to USD 2.88 Billion

Reuters
·
Aug 31

Eli Lilly: Under Terms of Agreement, Lilly Will Acquire Merida and Pay up to $2.875 Bln in Cash

THOMSON REUTERS
·
Aug 31

Lilly to Acquire Merida Biosciences to Advance Treatments for Serious Autoimmune and Allergic Diseases

THOMSON REUTERS
·
Aug 31

Eli Lilly - Deal Expected to Close in Q4 2026 Subject to Regulatory Approvals

THOMSON REUTERS
·
Aug 31

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

ETF Weekly | WXET, CRWL Surge 25%; SMST Sinks 18%; ZSL Jumps 9%; Inverse Metals and Small-Cap Bears Lead

ETF Weekly
·
Aug 29

India's GLP-1 Weight-Loss Drugs Stall at $14 Monthly Despite High Diabetes Rates

Deep News
·
Aug 29

Eli Lilly (LLY) Wins FDA Approval For Mounjaro Heart Risk Reduction

Simply Wall St.
·
Aug 29

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

MT Newswires Live
·
Aug 28